We have established a new transgenic mouse mutagenicity assay for the efficient detection of point mutations and deletions in vivo (Nohmi et al. [1996] Env. Mol. Mutagen. 28:465-470). In this assay, the gpt gene of Escherichia coli is used as a reporter for the detection of point mutations. Treatmen
Tissue-specific mutant frequencies and mutational spectra in cyclophosphamide-treated lacI transgenic mice
โ Scribed by Nancy J. Gorelick; Julie L. Andrews; Johan G. deBoer; Robert Young; David P. Gibson; Vernon E. Walker
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 103 KB
- Volume
- 34
- Category
- Article
- ISSN
- 0893-6692
No coin nor oath required. For personal study only.
โฆ Synopsis
The induction and nature of mutations in the lacI transgene were evaluated in multiple tissues after exposure of adult male B6C3F1 lacI transgenic mice to cyclophosphamide (CP). Mice were given a single i.p. injection of 25 mg CP/kg, 100 mg CP/kg, or vehicle (PBS) and then necropsied 6 weeks after treatment to allow DNA extraction and lacI mutant recovery. Tissues evaluated included target tissues for tumorigenesis (lung, urinary bladder) and sites not susceptible to tumor formation in B6C3F1 mice (kidney, bone marrow, splenic Tlymphocytes). After exposure to the high dose of CP, a significant increase in the mutant frequency (Mf ) was detected in the lungs and urinary bladders, compared to the respective tissues from vehicle-treated controls. In contrast, the Mfs in kidney, bone marrow, and splenic T cells from CP-treated mice were not significantly different from controls. The spectra of mutations in lacI from lung and urinary bladder were significantly changed after high-dose CP treatment, with a significant increase in the frequency of A โ T 3 T โ A transversions found in both tissues and a significantly elevated frequency of deletions in the lungs. Conversely, in vehicle-treated mice, the two predominant classes of lacI mutations recovered in lung and urinary bladder were G โ C 3 A โ T transitions at CpG sites and G โ C 3 T โ A transversions. These CP exposures were also genotoxic as measured by the significant induction of micronuclei in peripheral blood 48 hr after exposure. These data indicate that under these study conditions, CP-induced mutations are detectable in the lacI transgene in the target tissues, but not in nontarget tissues for CPinduced cancer. With the lacI assay it is possible to study mutagenicity in a variety of critical tissues to provide mechanistic information related to genotoxicity and carcinogenicity in vivo. Environ. Mol.
๐ SIMILAR VOLUMES
to the previously established Big Blue ยฎ assay. Genomic DNA isolated from liver, spleen, and lung tissue of control or ethylnitrosourea (ENU)-treated Big Blue ยฎ mice (100 mg/kg i.p., single dose) was packaged into phage (five animals, two packagings per DNA sample) which were simultaneously plated f
To investigate tissue-specific relations between DNA versions, expected from O 2 -ethylthymine. In bone adducts and mutagenesis in vivo, llacZ transgenic marrow after ENU treatment, a maximum mutation mice were treated i.p. with N-ethyl-N-nitrosourea induction occurred at 3 days post-treatment, of (